Traders should monitor upcoming Phase 1 readouts for STRO-004 in mid-2026 and IND filings for STRO-006 and STRO-227 later in the year. Positive clinical translation of preclinical data could drive significant upside, especially given Sutro’s platform differentiation in dual-payload ADCs.
Price Chart
Executive Summary
Sutro Biopharma presented promising preclinical data for its next-generation antibody-drug conjugates (ADCs), including STRO-004, STRO-006, and STRO-227, demonstrating robust antitumor activity and favorable safety profiles. The data reinforce confidence in Sutro’s platform and support upcoming IND filings and clinical readouts in 2026. Partner Astellas also highlighted positive preclinical results for its TROP2-targeted iADC, ASP2998.
Key Facts
- STRO-004 showed strong antitumor activity across TF-expressing solid tumor PDX models at a 5 mg/kg dose, with improved efficacy vs. benchmark ADCs and a high HNSTD of 50 mg/kg, indicating a wide therapeutic window.
- STRO-006 demonstrated dose-dependent antitumor activity in NSCLC and head and neck cancers, with IND submission planned for 2026.
- STRO-227, a dual-payload ADC targeting PTK7, showed superior efficacy over single-payload ADCs in breast, ovarian, and NSCLC models; IND filing expected late 2026.
- Astellas’ TROP2-targeted iADC ASP2998, developed using Sutro’s platform, entered clinical dosing earlier in 2026 and showed potent efficacy and immune activation in preclinical models.
Financial Impact
No direct financial impact disclosed; potential long-term value from clinical advancement and partnership milestones.
Risk Factors
- Preclinical success does not guarantee clinical efficacy.
- Development timelines may shift; IND filings and clinical results are subject to regulatory and operational risks.
- Competition in the ADC space is intensifying, particularly in TROP2 and PTK7 targets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276676 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.35 (−27.93%) |
Aug 12, 2026 7w ago | Press Release | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.35 (−27.93%) |
Apr 22, 2026 23w ago | DEFA14A | $34.83 $31.13 | ▼ −10.62% | ▼ −15.26% | $15.35 (−55.93%) |
Apr 19, 2026 23w ago | Press Release | $34.58 $34.48 | ▼ −0.29% | ▼ −4.49% | $15.35 (−55.61%) |
Mar 23, 2026 27w ago | S-3 | $23.57 $35.53 | ▼ −50.74% | ▼ −41.84% | $15.35 (+34.87%) |
Mar 23, 2026 27w ago | Press Release | $23.57 $35.53 | ▲ +50.74% | ▲ +41.84% | $15.35 (−34.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access